German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health to delve into the study of treatment response and resistance in metastatic hormone-sensitive prostate cancer. The collaborative project will leverage ClearNote’s epigenomic platform, which employs machine learning algorithms to analyze patient blood samples, monitor DNA-based changes, and provide insights for precision medicine.
ClearNote Health is known for its commercial blood test that detects pancreatic cancer signals in patients identified as being at high risk.- Flcube.com
